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Low Dose Rate prostate brachytherapy with 125Iodine & 103Palladium
Patricia Tai
Brachytherapy for cancer of the prostate can be performed using either low dose rate (LDR) or high dose rate (HDR)
techniques. LDR implants used permanent seeds of 125I or 103Pd. Clinically there seemed to be no clear difference in
treatment outcome between 103Pd and 125I. The American Brachytherapy Society (ABS) does not recommend one isotope in
preference to the other. The recommended prescription doses for monotherapy are 145 Gy for 125I and 125 Gy for 103Pd. The
corresponding boost doses, after 40 Gy to 50 Gy external beam radiotherapy, are respectively 110 Gy and 100 Gy. HDR, using
192Ir remote afterloading stepping sources, are not as popular as LDR brachytherapy. This review covers the physical and
radiobiological basis of permanent implants. Prostate cancer is one of the slowest growing carcinomas with a mean doubling
time of 577±68 days for those with a low Gleason score of <6, and 495±56 days for those with a high Gleason score of 6.
Tpot varies from 16 to 67 days. The α/β ratio for localized prostatic carcinoma is close to 1.5 Gy. The techniques of
brachytherapy have improved and currently the transperineal route is most commonly used. Traditionally pre-planning is
performed before the procedure and after the positions of the sources are verified in the CT scan, the final planning process is
made. However, intraoperative computer optimized conformal planning is now feasible. Patient selection is based on the
combination of clinical stage, PSA level, and biopsy Gleason score. If the gland size is between 40 g and 60 g, one should
perform a pubic arch study but avoid an implant if more than one-third of the prostate gland is blocked. Androgen ablation
may improve the efficacy of radiation therapy. There is little published literature regarding the use of permanent seed
implantation in the management of recurrent prostate cancer in patients who had been treated previously by radiotherapy of
the true pelvis.
Leczenie raka prostaty brachyterapià z zastosowaniem niskiej mocy dawki (LDR)
z wykorzystaniem izotopów jodu 125 lub palladu 103
Brachyterapia w raku prostaty mo˝e byç prowadzona z zastosowaniem zarówno wysokiej (HDR), jak i niskiej mocy dawki
(LDR). W przypadku stosowania techniki LDR wszczepia si´ albo izotop jodu 125 albo palladu 103. Obserwacje kliniczne nie
dostarczy∏y danych dotyczàcych ewentualnej wy˝szej skutecznoÊci jednego z tych izotopów. Amerykaƒskie Towarzystwo Bra-
chyterapeutyczne (American Barachytherapy Society – ABS) nie poleca ˝adnego z tych dwóch izotopów jako lepszego.
Dawki polecane w monoterapii si´gajà 145 Gy dla jodu 125 i 125 Gy dla palladu 103. Dla "boostu" po uprzednim podaniu
40-50 Gy ze êród∏a zewn´trznego dawki te wynoszà, odpowiednio, 110 Gy i 100 Gy. Technika brachyterapii z zastosowaniem
wysokiej mocy dawki (HDR), wykorzystujàca izotop irydu 192, nie jest tak popularna, jak brachyterapia z zastosowaniem ni-
skiej mocy dawki (LDR). Niniejsza praca poglàdowa przedstawia fizyczne i radiologiczne t∏o le˝àce u podstawy stosowania
trwa∏ych implantów.
Rak prostaty jest jednym z najwolniej rosnàcych nowowtworów. Âredni czas podwojenia guza si´ga 577±68 dni dla guzów z ni-
skim wskaênikiem Gleasona (<6) i 495±56 dni dla guzów z wysokim wskaênikiem Gleasona (6). W przypadku ograniczo-
nych raków prostaty stosunek α/β jest zbli˝ony do 1,5 Gy. Techniki stosowane w brachyterapii uleg∏y znacznej poprawie i obec-
nie najszerzej stosowana jest droga przezotrzewnowa. Tradycyjnie, przed rozpocz´ciem leczenia wykonuje si´ tzw. przedplano-
wanie. Ostateczne planowanie wykonuje si´ po umieszczeniu êróde∏ promieniowania i potwierdzeniu ich po∏o˝enia w obrazie
tomografii komputerowej. Niemniej w chwili obecnej mo˝liwe jest równie˝ komputerowe planowanie Êródoperacyjne. Pacjen-
ci sà dobierani zale˝nie od stopnia zaawansowania klinicznego, poziomu PSA i wartoÊci wskaênika Gleasona. Je˝eli gruczo∏
krokowy osiàga mas´ 40-60 g, nale˝y przeprowadziç ocen´ ∏uków koÊci ∏onowych i unikaç wprowadzania implantów, jeÊli za-
j´te jest wi´cej ni˝ 1/3 gruczo∏u. Ablacja androgenowa mo˝e przyczyniç si´ do poprawy skutecznoÊci radioterapii. Istnieje nie-
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Brachytherapy for cancer of the prostate can be perfor-
med using either low dose rate (LDR) or high dose rate
(HDR) techniques. As early as the 1920s radium needles
were implanted with in some cases, because of low activi-
ty needles, the sources remaining in situ for 18-20 days
and a typical dosage being 7000 milligram-hours. Radon
seeds of typical dimensions 7.5 mm length by 1 mm dia-
meter were an improvement on the use of radium, but
still far from ideal from the viewpoints of radiation safe-
ty, implantation technique, and size. Typically, 125I and
103Pd seeds are now 4.5 mm x 0.8 mm [1]. The LDR tem-
porary implants with 226Ra and 222Rn have now been to-
tally replaced by the modern permanent seed implants
using 125I or 103Pd. The use of permanently implanted
gold grains, the radionuclide 198Au, was essentially a trans-
itional stage and is now seldom used.
In this modern era, high dose rate (HDR) techni-
ques are also available, using 192Ir remote afterloading
stepping sources but they are not as popular as
LDR brachytherapy, in part, in the USA, due to cost
considerations in terms of reimbursement. However,
brachytherapy, either LDR or HDR, with its rapid dose
fall-off offers, when compared to external beam radio-
therapy, a potential advantage for reducing dose to nomal
structures, such as, bladder, rectum, small bowel and neu-
rovascular bundle at the periphery of the prostate gland.
It will continue to be an integral part of prostate cancer
available treatment technology for many years to come.
125Iodine & 103Palladium sources
P h y s i c a l  c o n s i d e r a t i o n s
125I has been widely used for permanent implants in pro-
state cancer and has, for example, an advantage over
198Au because of its long half-life of 60 days, see Table I,
which makes it convenient for storage. Also, because of its
low photon energy these sources require less shielding.
However, because of the presence of titanium end welds,
the dose distribution around 125I seeds is highly aniso-
tropic and this can pose problems by creating cold spots
near the source ends. The users of 125I implants either
ignore this problem or try to minimise the extent of cold
spots by creating a random seed distribution. 103Pd sources
have recently become available for use and have a shorter
half-life, 17 days, than that of 125I. The philosophy un-
derlying the development of 103Pd brachytherapy sour-
ces was a possible biological advantage in permanent im-
plants as the dose is delivered at a much faster rate.
Radiobiological considerations
Dicker has compared the radiobiological and treatment
planning effectiveness of 103Pd and 125I implants by using
the linear-quadratic model with recently published data
regarding: prostate tumour cell doubling times, Tpot, alpha
and alpha/beta ratio [2]. The tumour potential doubling
times (Tpot) were determined based on recently publi-
shed proliferation constants: fraction of cells prolifera-
ting per day, Kp, i.e. 1/Tpot. The initial slope of the cell ra-
diation dose survival curve, α, the terminal slope β and
the α/β ratio were taken from recent published clinical
and cellular results.
The total dose delivered from each isotope was the
dose used clinically, that is, 120 Gy for 103Pd and 145 Gy
for 125I. Dale’s modified linear-quadratic equation was
used to estimate the biological effective dose, the cell
surviving fraction, the effective treatment time, and the
wasted radiation dose for different values of Tpot. Treat-
ment plans for peripherally loaded implants were com-
pared. The Tpot reported for organ-confined prostate
carcinomas varied between 16 and 67 days. At short Tpot
both radionuclides were less effective, but 103Pd had much
less dependence on Tpot than 125I. However, at long Tpot
both radionuclides produced similar effects. The mini-
mum surviving fraction for exposure to 103Pd decreased
from 1.40 x 10-4 to 1.31 x 10-5 as the Tpot increased from 16
to 67 days. In contrast, for exposure to 125I, the minimum
surviving fraction decreased from 3.98 x 10-3 to 1.98 x 10-
5 over the same range of Tpot.
A comparison of treatment plans revealed that 103Pd
plans required more needles and seeds. This was a func-
wiele pubklikacji poÊwi´conych stosowaniu permanentnych implantów izotopowych w leczeniu nawracajàcych raków prosta-
ty u chorych leczonych uprzednio radioterapià na obszar miednicy.
Key words: prostate cancer, brachytherapy, implants
S∏owa kluczowe: rak prostaty, brachyterapia, implanty
Table I. Physical characteristics of radionuclides used in prostate LDR brachytherapy [1].
Notation: *unfiltered source in equilibrium with daughter products
Radionuclide Half-life Photon energy Half-value layer Exposure rate constant
(MeV) (mm lead) (Rcm2/mCi-h)
222Rn 3.83 days 0.047-2.45 8.0 10.15*∂
(0.83 mean)
198Au 2.7 days 0.412 2.5 2.38*
125I 60.2 days 0.028 mean 0.025 1.46*
103Pd 17.0 days 0.021 mean 0.008 1.48*
22
tion of seed strength. Both radionuclides had similar
dose-volume histograms (DVH) for prostate, urethra,
and rectum. The greatest benefit of 103Pd was shown to be
with tumours with a short Tpot. Although the regrowth
delay would be longer with 125I, the benefit was inconse-
quential compared with the very slow doubling times of
localised prostate cancer. Treatment planning with either
radionuclide revealed no significant differences. These
findings may explain why clinically there seemed to be
no clear difference in treatment outcome between 103Pd
and 125I.
The American Brachytherapy Society (ABS) does
not recommend one isotope in preference to the other
[3]. This is despite the fact that implantation with 103Pd
resulted in lower radiation doses to the rectum, the choice
of radionuclide was not predictive of bowel function
scores in a patient survey [4]. The 103Pd implants were
more greatly affected by fixed amounts of oedema than
were 125I implants, and the slopes of the DVH curves
indicate less homogeneity from 103Pd implants [5].
Perspective on technique
Re t r o p u b i c  v e r s u s  t r a n s p e r i n e a l  a p p r o a c h
In the 1970s, prostate implant was initially started via
a retropubic approach. The 15-year outcome of the his-
torical series of retropubic implantation from the
Memorial Sloan-Kettering Cancer Center has served as
the framework for the current transperineal implant
approaches used in the treatment of localised prostatic
cancer [6].
Between March 1970 and December 1987 a total of
1078 patients with biopsy proven adenocarcinoma of the
prostate were treated with permanent implantation of
125I seeds via a retropubic approach. In addition, all
patients underwent bilateral pelvic lymphadenectomy
before implantation. The clinical stages of disease were
B1 in 234 patients (22%), B2 in 472 (44%), B3 in 145
(14%) and C in 227 (20%). Of these patients 733 (68%)
had pathologically negative lymph nodes, whereas 345
(32%) had positive lymph nodes at lymph node dissection.
Median follow-up was 11 years.
Multivariate analysis identified nodal involvement,
high-grade disease, clinical stage B3/C and implant doses
less than 140 Gy, as independent predictors of local re-
lapse. The local recurrence-free survival rates for patients
with negative nodes at five, 10 and 15 years were respec-
tively 69%, 44% and 24%. The distant metastases-free
survival rates at five, 10 and 15 years for patients with
negative lymph nodes were respectively 59%, 36% and
21%. Therefore these results showed that 125I implanta-
tion of the prostate via the retropubic approach was asso-
ciated with a greater than expected incidence of local re-
lapse at 15 years. Technical limitations of the retropubic
technique resulting in suboptimal distribution of the
125I seeds within the prostate are believed to be the expla-
nation for the inferior local control outcome [6]. Later
transperineal interstitial permanent prostate brachy-
therapy has become an increasingly popular treatment
for early stage, favourable risk adenocarcinoma of the
prostate.
H i g h  s t r e n g t h  v e r s u s  l o w  s t r e n g t h  s e e d s
Two common dosimetric philosophies for prostate
implants are the use of many low activity seeds versus
relatively fewer seeds of higher activity [7-9]. When fewer
seeds of higher strength are used, individual seeds at the
periphery of the gland rely on the higher activity of the
seeds and proper placement to deliver sufficient doses
to the central portion of the gland. The theoretical advan-
tage of this technique is avoidance of high central doses,
particularly to the urethra and the reduced number of
needles/catheters required for the positioning of the
sources for the implant. However, the theoretical disad-
vantage is that high doses may subsequently be delivered
to the periphery: that is, to the rectum and neurovascular
bundle.
Modern uniform seed loading requires more seeds
(of lower activity) than peripheral loading, with general-
ly, uniform 1 cm spacing of the seeds throughout the
prostate. The advantage of this approach is that the dose
delivered to any point is less dependent on the nearest
seed and therefore this may be more forgiving than the
peripheral technique. However, strict adherence to uni-
form spacing can lead to high doses to the urethra, par-
ticularly in large glands. In practice, a combination of
philosophies is frequently used to optimise each
patient’s implant. 125I has been called a more forgiving
radionuclide because the higher energy, 28 keV, has
a slightly greater penetration distance than the 21 keV
photons of 103Pd.
I n t r a o p e r a t i v e  u l t r a s o u n d  g u i d a n c e
Intraoperative real-time ultrasound guided technique is
nowadays most commonly used and after completion of
the implant a series of CT scans is then performed to do-
cument the source positions. Recent studies have demon-
strated that magnetic resonance spectroscopic imaging
(MRSI) of the prostate may effectively distinguish be-
tween regions of cancer and regions of normal prostatic
epithelium [10]. This diagnostic imaging tool takes ad-
vantage of the increased choline and creatine versus citra-
te ratio found in malignant, compared with normal, pro-
state tissue.
C o m p u t e r  o p t i m i s e d  c o n f o r m a l  p l a n n i n g
Traditionally pre-planning is performed before the pro-
cedure and after the positions of the sources are verified
in the CT scan, the final planning process is made.
However, intraoperative computer optimised conformal
planning is now feasible [11-13] and is not too time-con-
suming so as to delay the operation time. The average
time for the intraoperative procedure is 1.74 hours [12].
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Treatment decisions
O r g a n - c o n f i n e d  d i s e a s e ,  s t a g e s  T 1 a - c &
T 2 a - c
For clinically organ-confined prostate cancer stages T1a-c
and T2a, Gleason score <7 and PSA <10 ng/ml, implant
alone is adequate. Otherwise add 45 Gy external beam
radiotherapy. The rule of thumb is that whenever the risk
for extracapsular disease is high, the patient should
receive pelvic external beam radiation [14].
Interstitial prostate brachytherapy for patients with
a PSA level of <10 ng/ml yields at least a 87% rate of
freedom from biochemical relapse at three years, which is
numerically equivalent to results achieved with external
beam radiotherapy or radical prostatectomy [15]. The
combination of clinical stage, PSA level, and biopsy
Gleason score allows for the selection of patients with
the highest probability of having all of the prostate cancer
encompassed by the high dose implant volume, while
simultaneously respecting the normal tissue tolerance
doses of the rectum and bladder. In particular, patients
with non-palpable, T1c, lesions, a biopsy Gleason score of
6, or ideally 4, and a PSA level of <10 ng/ml represent
the optimal implant candidates.
P r i o r  T U R P
For patients with a previous transurethral resection of
the prostate (TURP) the optimum strategy is to avoid
an implant if there is a large defect due to excessive ure-
thral toxicity. If there is only a small defect, explain the
risks to the patient and proceed with an implant if he
consents.
G l a n d  s i z e s  >  6 0  g ,  o r  4 0 - 6 0  g
If the prostate gland size is more than 60 g, consider
using a hormonal blockade but avoid an implant. If the
gland size is between 40 g and 60 g, perform a pubic arch
study but avoid an implant if more than one-third of the
prostate gland is blocked. Androgen ablation may im-
prove the efficacy of radiation therapy [16].
A total of 296 patients who had either 125I (206/296)
or 103Pd (90/296) transperineal prostate brachytherapy
without any external beam radiation therapy, had a routi-
ne Transrectal Ultrasound TRUS guided needle biopsy
with a minimum of six cores, at two years post-treatment
without regard to disease status. It was shown that
prostate brachytherapy yields a high negative biopsy rate
of 90% at two years after treatment. Neoadjuvant hor-
monal therapy (NHT: leuprolide acetate and flutamide)
was used in 115/296 patients for three months prior to
and three months after the implant. Of the 296 patients
only a total of 30 had positive prostate biopsies. Biopsies
were respectively positive in 4/115 versus 26/181 of those
who received or had not received NHT, P = 0.002 [16].
N e o a d j u v a n t  h o r m o n a l  t h e r a p y  &  g l a n d  
s i z e  r e d u c t i o n
When patients were separated into low risk (PSA 10
ng/ml, stage T2a and Gleason score 6) and high risk
groups (PSA >10 ng/ml, stage >T2a and Gleason
score >6), it was seen that low risk patients did not bene-
fit from NHT (3.8% versus 7.7% positive biopsy rate:
P = 0.5) whereas high risk patients did benefit from NHT
(3.4% versus 21.1%: P = 0.003). With neoadjuvant hor-
monal therapy, the prostate gland sizes were reduced and
this facilitated brachytherapy. The mean prostate volume
(PV) after NHT was 31 cm3 (range 11.7-73.7 cm3) [17].
The mean PV reduction was 35% (range 2-62%). Volume
reduction was compared in those 51 patients who pre-
sented with a PV <40 cm3 and those 56 with a PV 40.
The mean reduction for the smaller glands was 29%
(range 2-54%) compared with 41% (range 7-62%) for
the larger glands, P <0.05.
A s p i r i n  &  a n t i c o a g u l a n t s
There should be no bleeding disorder and patients on
regular aspirin or anticoagulants should stop at least seven
days before implantation [18].
P r i o r  r a d i o t h e r a p y  o f  t h e  t r u e  p e l v i s
There is little published literature regarding the use of
permanent seed implantation in the management of pri-
mary and recurrent prostate cancer in patients who had
been treated previously by radiotherapy of the true pelvis.
Battermann has reported on a total of 21 patients who
received an 125I implant after radiotherapy for bladder
cancer (2/21), anal cancer (1/21), seminoma (2/21) and
prostate cancer (16/21) [19]. Two seminoma and 10
prostate cancer patients were treated after previous defini-
tive external beam radiation therapy, while the bladder
and anal cancer were initially treated with external beam
radiotherapy plus a 192Ir implant. Six of the prostate can-
cer patients were initially treated by brachytherapy alone.
After previous external beam radiotherapy, no serious
late toxicity was observed with permanent seed implants.
However, one of the six patients who had two
125I seed implants experienced serious complications
which resulted in a vesico-rectal fistula. The permanent
seed implantation with 125I is feasible after previous radio-
therapy in the prostate area but experience is very preli-
minary and the efficacy of treatment remains to be proven
by further series from other centres. A second implant is
also possible but may result in severe complications,
depending on the initial dose and the interval between the
two treatments [19].
Grado has published results of 49 patients with pre-
vious external beam radiation and three with 125I seed
implants as primary radiotherapy [20]. Salvage brachy-
therapy achieved a high rate of local control and a 34%
actuarial rate of biochemical disease-free survival at five
years. The incidence of major complications after salvage
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brachytherapy appears to be lower than that after other
potentially curative salvage procedures, such as radical
prostatectomy and cryoablation.
Treatment planning
In the Seattle technique for an 125I implant, the treated
volume is calculated as the volume encompassed by the
144 Gy isodose distribution [21]. A post-implant compu-
ted tomography scan is obtained the following day, using
5 mm slices for the images. The prostate margin is taken
to be the gross tumour volume (GTV). This group is cur-
rently using 5 mm treatment margins around the GTV, as
identified on pre-implant TRUS images or on CT scans.
However, the poor correlation between planned and actu-
al post-implant treatment margins calls into question any
attempt to make a rational recommendation regarding
optimal treatment margins.
The recent American Brachytherapy Society recom-
mendations for permanent prostate brachytherapy [3]
recommends treating patients with a high probability of
organ-confined disease with brachytherapy alone. Bra-
chytherapy candidates with a significant risk of extra-
prostatic extension should be treated with supplemental
external beam radiotherapy.
The recommended prescription doses for monothe-
rapy are 145 Gy for 125I and 125 Gy for 103Pd. The corre-
sponding boost doses, after 40 Gy to 50 Gy external beam
radiotherapy, are respectively 110 Gy and 100 Gy. The
ABS also recommends that post-implant dosimetry should
be performed on all patients undergoing permanent
prostate brachytherapy for optimal patient care. A DVH
of the prostate should be performed and the dose to 90%
of the prostate gland, D(90), be reported by all centres.
Additionally, the D(80) D(100), the fractional V(80),
V(90), V(100), V(150), V(200), that is, the percentage of
the prostate volume receiving respectively 80%, 90%,
100%, 150%, and 200% of the prescribed dose, and the
rectal and urethral doses should also be reported. The
detailed reports of the American Association of Physicists
in Medicine (AAPM) recommendations for 125I by the
AAPM Task Group 43 [22] and for 103Pd [23] should be
consulted.
Treatment results & dose-response relationship
New York Mount Sinai School of Medicine have reported
excellent treatment results with brachytherapy [24]. Im-
plants were performed using a real-time ultrasound
guided technique with 125I in 186 patients and 103Pd in
82 patients. The implant dose was defined as the D(90)
dose delivered to 90% of the gland from the DVH gene-
rated using one-month post-implant CT based dosimetry.
Overall, 89% of patients (238/268) had negative biopsies
and therefore a positive biopsy could be considered to
be a good predictor of biochemical failure. Patients with
a positive biopsy had a five-year freedom from biochemi-
cal failure of 40% versus 76% for patients with a negative
biopsy, P=0.0003. Univariate and multivariate analyses
found that risk group, hormonal therapy and implant
dose significantly affected biopsy outcome.
A total of 104 patients with low risk features
(PSA 10 ng/ml; Gleason score 6; and stage T2a or
lower) had a negative biopsy rate of 95% versus 85%
when compared with 168 patients with high risk features
(PSA >10 ng/ml, Gleason score 7 or stage T2b),
P=0.008.
The 174 patients receiving a high implant dose, defi-
ned as D(90) 140 Gy for 125I or 100 Gy for 103Pd, had
a negative biopsy rate of 95% versus 77% compared with
those 87 patients receiving a low dose, defined as D(90)
<140 Gy for 125I or <100 Gy for 103Pd, P<0.001.
Memorial Sloan-Kettering Cancer Centre results for
five-year biochemical outcome with transperineal CT
planned permanent 125I prostate implants [25] were as
follows. A total of 38 (15%) patients developed a PSA
relapse and the overall five-year PSA relapse-free sur-
vival (PRFS) rate was 71%. The five-year PRFS rates for
the favourable risk group of 146 patients, the 85 cases in
the intermediate risk group and the 17 in the
unfavourable risk group were respectively 88%, 77%, and
38%, P<0.0001. The five-year PRFS rates among patients
treated with a two month course of neoadjuvant androgen
deprivation prior to transperineal implant (TPI) com-
pared to patients treated with TPI only were respectively
100% and 77%, P=0.03. Multivariate analysis identified
pretreatment PSA >10 ng/ml and Gleason score >6 as
independent predictors for biochemical relapse after TPI.
Transient elevation of serum PSA after
brachytherapy
It is important to emphasise that serum PSA sometimes
exhibits a transient elevation. This causes a lot of anxiety
for both the patient and physician. In patients judged
biochemical successes at their last follow-up, serum PSA
1.0 ng/ml, 35.8% exhibited a temporary increase of
0.2 ng/ml or more [26]. 75% of these patients exhibited
a temporary increase between 0.3 ng/ml and 3.4 ng/ml.
The average time of the temporary increases was 24.8
months after implant. Spiking was not associated with
a higher risk of clinical failure in this data set. The aetio-
logy of PSA bounce is probably due to late developing
radiation prostatitis [27].
Men often experience urinary symptoms during ra-
diation treatment followed by a resolution of symptoms
within a few months of treatment. Between 12 and 24
months after treatment recurrent urinary symptoms
may develop, indicating delayed radiation prostatitis. This
time frame corresponds to the time that PSA bounce
is most frequently observed. A further support of this
association is that the PSA bounce was uncommon when
a PSA nadir 0.2 ng/ml or less was achieved, a level that
reflects little or no existing benign epithelium that could
become inflamed.
25
Complications
Acute complications which can occur before six months
has elapsed following treatment are given in Table II and
the chronic complications which can occur later than six
months post-treatment are given in Table III. The compli-
cation percentage incidence figures are taken from the
Teaching Course of the Seattle Prostate Institute where
many physicians have been trained before starting their
own brachytherapy programme.
Table II. 
Acute complications which can occur <6 month post-treatment
1. Dysuria occurs in almost all cases. Can start immediately after the
implant or about a week post-implant.
2. Hematuria is common for first 24 hours. Protracted hematuria
occurs in  5-7%.
3. Perineal hematoma as a minor complication is common. In only
fewer than 3% is this a significant complication. 
4. Obstruction occurs in 5-12% but is more of a problem in the acute
post-implant phase.
5. Perineal pain/orchalgia occurs in fewer than 5%.
6. Diarrhoea/rectal urgency occurs in fewer than 10%.
7. Musculoskeletal aches and pains occur in fewer than 2%.
8. Constipation occurs in more than 20%.
9. Prostatitis is very common.
10. Ejaculatory pain/hematospermia is common.
11. Acute proctitis occurs in fewer than 2%.
Table III. 
Chronic complications which can occur at >6 months post-treatment
1. Chronic cystitis occurs in 3-7%.
2. Incontinence occurs in fewer than 1%.
3. Rectal ulceration occurs in fewer than 1%.
4. Obstruction/urinary retention occurs in fewer than 3%.
5. Urethral necrosis occurs in fewer than 1%.
6. Complete erectile dysfunction occurs in 20-25% 
and partial erectile dysfunction in 20-25%.
With a minimum median follow-up time of 24
months, 81% to 85% two-year actuarial and three-year
crude potency rates have been reported concomitantly
with two-year actuarial rates of 12% for  grade 2 rectal
complications and 10% for  grade 3 urethral compli-
cations [15]. Differential loading of the implant away
from the geometrical centre and not accepting as implant
candidates those patients with large prostate glands,
defined as  60 cm3, or a history of transurethral resec-
tion of the prostate, may reduce urethral toxicity.
In a patient survey, a trend toward increased rectal
symptoms was noted for older patients, and a non-signifi-
cant improvement in rectal survey scores was noted with
elapsed time from implantation [4]. Only 19.2% (40/208)
of the treatment group reported a worsening of bowel
function following implantation. To date, no severe chan-
ges in late bowel function have been noted following pro-
state brachytherapy. Although the survey scores indicate
bowel function is worse after an implant, the minor chan-
ges are not significant enough to cause any real problem
to most individuals. Less than 20% of patients reported
that their bowel function was worse following prostate
brachytherapy.
In another report, serious rectal injury was again
shown to be very rare [28]. Only seven prostatourethral-
rectal fistula (PRF) developed in 754 patients between
nine and 12 months after treatment [29]. One PRF
occurred in a patient who was treated with brachytherapy
alone. PRFs occurred in 2/69 patients who were treated
with combination brachytherapy and external beam
therapy and in 4/43 patients who underwent salvage
brachytherapy. All six patients who developed fistulas in
the context of combination brachytherapy and external
beam therapy or salvage brachytherapy had biopsies of
an anterior rectal lesion overlying the prostate noted on
physical examination during routine follow-up.
Gastrointestinal endoscopic evaluation alone was
not associated with any PRF. 5/7 PRFs resolved with
either surgical repair, 3/5, or conservative management,
2/5. Because all patients who developed PRF did so sub-
sequent to prior rectal biopsies, the authors currently are
strongly discouraging such practices if the rectal lesion
is consistent with radiation-induced effects.
Development of erectile dysfunction following
radical therapy is a particular concern, and occurs in
perhaps one-third of patients treated by radiotherapy and
30-70% of patients treated by radical prostatectomy [30].
Although it is assumed that the erectile dysfunction rela-
tes to damage to the nerves subserving erection, this view
has been questioned recently and in at least a propor-
tion of patients the cause appears to be vascular. Despite
the likely cause of their erectile dysfunction, all patients
presenting with erectile dysfunction after treatment for
prostate cancer should undergo assessment by history
and examination to ensure that there are no other correc-
table risk factors. Patients can then be considered for
a number of treatment options, and currently sildenafil
(Viagra, Pfizer) is usually used as first-line therapy assu-
ming there are no contraindications, such as severe ischa-
emic heart disease or nitrate therapy.
Sildenafil improves erectile function in 70% of
patients with erectile dysfunction post-radiotherapy, but
appears less effective in men after radical prostate surgery
when there is a response rate of 40-50%. Other treat-
ment options include self-injection or intra-urethral admi-
nistration of alprostadil, and some patients are happy to
use a vacuum erection device. Finally, if all else fails,
patients may be suitable for penile implant surgery.
Advantages & limitations of LDR compared 
with HDR
For prostate brachytherapy LDR is more convenient than
HDR. It requires six hours in hospital versus 24 hours for
HDR. LDR is also simpler for a department to start up
a prostate brachytherapy programme if they do not have
an HDR unit or interstitial HDR experience.
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LDR requires a long initial learning curve. Perma-
nent seeds must be placed exactly as intended, or cold
and hot spots will occur. If a cluster of seeds is placed
near the rectum this hot spot can cause a fistula and a cold
spot cannot easily be corrected. With HDR, catheters can
be removed or adjusted under CT guidance and varia-
ble HDR catheter spacing is corrected by geometric opti-
misation. An HDR implant can be aborted if dosimetry is
not ideal, however, the only way to abort an LDR im-
plant is to perform a prostatectomy. Figure 1 shows an ul-
trasound scan performed for estimation of the prostate
gland volume, which can be measured by the physicist or
technologist easily. Figure 2 shows a HDR implant with
relatively good distribution of catheters. Further adjust-
ment by loading the source for different time periods can
achieve good dosimetry. On the other hand, HDR also
has its own problems: such as guide movement between
the CT scan and treatment and also between the treat-
ment sessions [31]. Also, since the treatment can be com-
pleted in a shorter time for HDR, the effect of edema is
less than for LDR.
Volume studies are used in advance with LDR seed
implants because it is difficult and expensive to under-
take real-time dosimetry during the seed implant and the
number of seeds to be ordered can be determined by the
volume study. However, it is difficult to position the pro-
Figure 2. Shows a HDR implant with relatively good distribution of catheters. Further adjustment
by loading the source for different time periods can achieve good dosimetry
Figure 1. Shows an ultrasound scan performed for estimation of the prostate gland volume, which
can be measured by the physicist or technologist easily
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state in exactly the same way during the actual seed im-
plant procedure.
Seeds can migrate to the lung or spine, or can be
urinated out of the patient. Patients may be concerned
about this possibility. Loss of seeds may cause a cold spot
in the prostate and the prostatic base may not be well
covered by the seeds. During an HDR implant procedure,
cystoscopy is performed to ensure that the catheters are
pushed in as far as possible. HDR dwell times can be ad-
justed to allow a ballooning of the isodose at base to give
the full prescribed dose.
Permanent seeds cost US$ 5,000 or more per pa-
tient, versus a HDR cost of US$ 30,000 per year to main-
tain. However, a HDR machine can be used for other
purposes such as bronchus, oesophagus, etc.
Permanent implants take into consideration cell inac-
tivation by protracted irradiation, repair of sublethal ra-
diation damage during the radiation delivery, tumour cell
repopulation, and the exponentially decreasing radiation
dose rate. Prostate cancer is one of the slowest growing
carcinomas with a mean doubling time of 577±68 days for
those with a low Gleason score of <6, and 495±56 days
for those with a high Gleason score of 6 [32]. Tpot varied
from 16 to 67 days [33]. The α/β ratio for localised prosta-
tic carcinoma is close to 1.5 Gy [34]. 125I requires six mon-
ths to give 87% of its dose at an average dose rate of
3.7 cGy/hour. HDR gives 550 cGy in five minutes. Final-
ly, it is noted that Duchesne’s editorial in the Int J Radiat
Oncol Biol Phys favours HDR afterloading brachytherapy
over permanent seed implants [35].
Comparison of brachytherapy with other treatment
modalities
A study from the Joint Centre for Radiation Therapy at
Harvard [36] on 194 men treated with radical prostatecto-
my for clinically localised prostate cancer between 1995-
1996 examined if the anterior prostatic base needs to be
treated by brachytherapy. Of 269 foci of prostate cancer
found in 39 low risk prostate cancer patients (PSA <10
ng/ml, biopsy Gleason score 6, and 1992 AJCC clinical
stage T1c, 2a), only a single focus, representing 0.37%
of this patient series, was noted in the anterior base.
Conversely, 20/355 (5.6%) and 18/251 (7.2%) tumour
foci were noted in the anterior base in 43 patients with
intermediate risk and in 24 patients with high-risk disease,
respectively. Therefore for intermediate and high risk
disease, external beam radiotherapy should be able to
provide a better target volume coverage.
This is also reflected in another publication [37].
This retrospective cohort study consisted of a total of
1872 men treated between January 1989 and October
1997 with a radical prostatectomy (888/1872) or implant
with or without neoadjuvant androgen deprivation
therapy (218/1872) at the Hospital of the University of
Pennsylvania, or external beam radiotherapy (766/1872) at
the Joint Centre for Radiation Therapy, Boston. The
relative risks (RR) of PSA failure in low risk patients
(stage T1c, T2a, PSA 10 ng/ml and Gleason score 6)
treated using radiotherapy, implant plus androgen
deprivation therapy, or implant therapy alone were
respectively RR=1.1 (95% CI of 0.5-2.7), RR=0.5
(95% CI of 0.1-1.9), and RR=1.1 (95% CI of 0.3-3.6),
compared with those patients treated with RP.
The relative risks of PSA failure in the intermediate
risk patients (stage T2b, Gleason score = 7, PSA >10
and 20 ng/ml) and high risk patients (stage T2c, PSA
>20 ng/ml, Gleason score 8) treated with implant com-
pared with radical prostatectomy were respectively
RR=3.1 (95% CI of 1.5-6.1) and RR=3.0 (95% CI of
1.8-5.0).
Therefore low risk patients had estimates of five-
year PSA outcome after treatment with radical prosta-
tectomy, external beam radiotherapy, or implant with or
without neoadjuvant androgen deprivation that were not
statistically different, whereas intermediate risk and high
risk patients treated with radical prostatectomy or radio-
therapy had a better outcome then those treated by im-
plant.
Although prospective randomised trials are needed
to verify these findings, the implication appears to be
that brachytherapy alone is inferior in intermediate risk
and high risk disease since coverage of the anterior base
and extracapsular spread is inadequate. Implant brachy-
therapy therefore has to be combined with external beam
radiotherapy.
Seed implants are associated with greater morbidity
than external beam radiotherapy. For example, Zelefsky
has published the results of a study comparing the
3D conformal radiotherapy (3DCRT) with transperineal
prostate 125I seed implant (TPI) [38]. A total of 11
patients (8%) in the 3DCRT group and 12 patients (8%)
in the TPI group developed a biochemical relapse. The fi-
ve-year PSA relapse-free survival rates for the 3DCRT
and the TPI groups were respectively 88% and 82%,
P =.09. Protracted grade 2 urinary symptoms were more
prevalent among patients treated with TPI compared
with those in the 3DCRT group. Grade 2 urinary toxicity,
which manifested after the implant and persisted for more
than one year after this procedure, was observed in 45
patients (31%) in the TPI group. In these 45 patients,
the median duration of grade 2 urinary symptoms was
23 months, range 12-70 months.
On the other hand, acute grade 2 urinary symptoms
resolved within 4-6 weeks after completion of 3DCRT,
and the five-year actuarial rate of late grade 2 urinary
toxicity for the 3DCRT group was only 8%. The five-year
actuarial rate of developing a urethral stricture, classi-
fied as a grade 3 urinary toxicity, for the 3DCRT and TPI
groups were respectively 2% and 12%, P<.0002. Of 45
patients who developed grade 2 or higher urinary toxicity
after TPI, the likelihood of a resolution or significant im-
provement of these symptoms at 36 months from onset
was 59%. The five-year likelihood of grade 2 late rectal
toxicity for the 3DCRT and TPI patients was similar:  6%
and 11% respectively, P=.97.
No patient in either group developed any grade 3 or
higher late rectal toxicity. The five-year likelihood of post-
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treatment erectile dysfunction among patients who were
initially potent before therapy was 43% for the 3DCRT
group and 53% for the TPI group, P=.52. In conclusion,
both 3DCRT and TPI are associated with an excellent
PSA outcome for patients with early stage prostate can-
cer. Urinary toxicities are more prevalent for the TPI
group but subsequently resolve or improve in most pa-
tients.
Conclusions
This review has raised various issues. For low risk pa-
tients, both brachytherapy and 3DCRT produce similar
treatment results in different series. One could argue that
the outcome for these patients is in any event good with
such a short follow-up period no matter what treatment
modality is chosen. Brachytherapy has more morbidity
and is more invasive, labour-intensive, and expensive than
3DCRT.
For intermediate-risk and high-risk patients, target
coverage with brachytherapy may not be as good as with
3DCRT since the anterior base and any extracapsular
spread are not adequately covered. However, theoreti-
cally, brachytherapy has a higher tissue dose surrounding
the radioactive sources than does 3DCRT, provided that it
can be shown that the dose-response is important for
prostate cancer. We are waiting for the result of the
RTOG 3DCRT dose escalation studies.
In the future, a randomised trial of the most optimal
dose of 3DCRT as a sole modality versus brachytherapy
combined with 3DCRT for intermediate risk and high-risk
patients may be able to resolve the issue for these risk
groups.
Patricia Tai
Department of Radiation Oncology
Allan Blair Cancer Centre
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Regina
Saskatchewan S4T 7T1
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